Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2012-002856-18-FR
EUCTR2012-002856-18-FR
Active, not recruiting
Not Applicable

ALdosterone antagonist Chronic HEModialysis Interventional Survival Trial - ALCHEMIST

CHRU de Brest0 sitesJune 14, 2013
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
CHRU de Brest
Status
Active, not recruiting
Last Updated
12 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 14, 2013
End Date
TBD
Last Updated
12 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
CHRU de Brest

Eligibility Criteria

Inclusion Criteria

  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1\.2 Adults (18\-64 years) yes
  • •F.1\.2\.1 Number of subjects for this age range
  • •F.1\.3 Elderly (\>\=65 years) yes
  • •F.1\.3\.1 Number of subjects for this age range
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1\.2 Adults (18\-64 years) yes
  • •F.1\.2\.1 Number of subjects for this age range

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
ALdosterone antagonist Chronic HEModialysis Interventional Survival Trialend-stage renal failure (ESRF)cardiovascular complicationMedDRA version: 20.0Level: PTClassification code 10007649Term: Cardiovascular disorderSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 20.0Level: LLTClassification code 10050441Term: Chronic renal insufficiencySystem Organ Class: 100000004857Therapeutic area: Body processes [G] - Metabolic Phenomena [G03]
EUCTR2012-002856-18-BECHRU de Brest825
Completed
Phase 3
ALdosterone Antagonist Chronic HEModialysis Interventional Survival TrialEnd Stage Renal Failure on Dialysis
NCT01848639University Hospital, Brest823
Active, not recruiting
Not Applicable
Aldosterone receptor blockade in patients with chronic kidney disease.Influence on arterial stiffness and kidney function. - ALBLOCK-2Chronic kidney disease, stages 3 and 4.MedDRA version: 9.1Level: LLTClassification code 10064848Term: Chronic kidney disease
EUCTR2009-012445-35-DKHerlev Hospital80
Active, not recruiting
Not Applicable
ALDOSTERONE RECEPTOR BLOCKADE IN DIASTOLIC HEART FAILUREA double-blind, randomised, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure - Aldo-DHF
EUCTR2006-002605-31-DEGeorg-August-Universität Göttingen
Active, not recruiting
Not Applicable
ALDOSTERONE RECEPTOR BLOCKADE IN DIASTOLIC HEART FAILUREA double-blind, randomised, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure - Aldo-DHFDiastolic Heart FailureMedDRA version: 8.1Level: LLTClassification code 10008908Term: Chronic heart failure
EUCTR2006-002605-31-ATGeorg-August-Universität Göttingen420